Patterns of Response to Different Treatment Strategies in Seropositive Rheumatoid Arthritis Patients in a Tertiary Hospital in South‐Western Saudi Arabia: A Retrospective Study

References

• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(S1):1–12. doi:10.2165/00019053-200422001-00002
   Web of Science ®Google Scholar
• Al-Dalaan A, Al Ballaa S, Bahabri S, Biyari T, Al Sukait M, Mousa M. The prevalence of rheumatoid arthritis in the Qassim region of Saudi Arabia. Ann Saudi Med. 1998;18(5):396–397. doi:10.5144/0256-4947.1998.396
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. doi:10.1136/annrheumdis-2015-207524
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655
   PubMed Web of Science ®Google Scholar
• Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice: ACR RA Disease Activity Measures Recommendations. Arthritis Care Res (Hoboken). 2012;64(5):640–647. doi:10.1002/acr.21649
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Dhaon P, Das SK, Srivastava R, Dhakad U. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. Int J Rheum Dis. 2018;21(11):1933–1939. doi:10.1111/1756-185X.13110
   Web of Science ®Google Scholar
• Almoallim HM, Alharbi LA. Rheumatoid arthritis in Saudi Arabia. Saudi Med J. 2014;35(12):1442–1454.
   PubMed Web of Science ®Google Scholar
• Dargham SR, Zahirovic S, Hammoudeh M, et al. Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. PLoS One. 2018;13(12):e0208240. doi:10.1371/journal.pone.0208240
   Web of Science ®Google Scholar
• Bawazir YM. Clinicodemographic profiles of rheumatoid arthritis patients from a single center in Saudi Arabia. Open Access Rheumatol. 2020;12:267–275. doi:10.2147/OARRR.S277956
   PubMed Web of Science ®Google Scholar
• Masi AT, Maldonado-Cocco JA, Kaplan SB, Feigenbaum SL, Chandler RW. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum. 1976;5(4):299–326. doi:10.1016/0049-0172(76)90013-5
   Google Scholar
• de Vries-bouwstra JK, Goekoop-Ruiterman YPM, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum. 2008;58(5):1293–1298. doi:10.1002/art.23439
   Web of Science ®Google Scholar
• Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196–201. doi:10.1136/ard.2003.019992
   PubMed Web of Science ®Google Scholar
• Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore). 2013;92(2):92–97. doi:10.1097/MD.0b013e318289ce01
   PubMed Web of Science ®Google Scholar
• Omair MA, Omair MA, Halabi H. Survey on management strategies of rheumatoid arthritis in Saudi Arabia: a Saudi Society for Rheumatology Initiative. Int J Rheum Dis. 2017;20(9):1185–1192. doi:10.1111/1756-185X.12735
   Web of Science ®Google Scholar
• Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68(7):1105–1112. doi:10.1136/ard.2008.099861
   PubMed Web of Science ®Google Scholar
• Sepriano A, Ramiro S, FitzGerald O, et al. Adherence to treat-to-target management in rheumatoid arthritis and associated factors: data from the international RA BIODAM cohort. J Rheumatol. 2020;47(6):809–819. doi:10.3899/jrheum.190303
   Web of Science ®Google Scholar
• Provan SA, Austad C, Halsaa V, Hammer HB, Kvien TK, Uhlig T. Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. Clin Exp Rheumatol. 2019;37 Suppl 116(1):58–62.
   Web of Science ®Google Scholar
• Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2011;70(3):469–475. doi:10.1136/ard.2010.139212
   PubMed Web of Science ®Google Scholar
• Almoallim H, Hassan R, Cheikh M, et al. Rheumatoid arthritis Saudi database (RASD): disease characteristics and remission rates in a tertiary care center. Open Access Rheumatol. 2020;12:139–145. doi:10.2147/OARRR.S260426
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183–192. doi:10.1016/j.semarthrit.2017.03.008
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276–289. doi:10.1038/nrrheum.2015.8
   PubMed Web of Science ®Google Scholar